top of page

Publicações

Algumas publicações da Axia.Bio:

Livros

Através de sua participação na ISPOR, membros da nossa equipe colaboraram para a edição e publicação dos livros: "Custo em Saúde, Qualidade e Desfechos: O Livro de Termos da ISPOR" e "Investigação de Desfechos de Dispositivos Diagnósticos e Terapeuticos" em português.

  • Medical resource use and direct medical cost of chronic hepatitis C virus infection (HCVI) in Brazil - Value in Health, Vol. 8, Issue 6, A122–A123

 

  • The cost-effectiveness of peginterferon alfa-2b (i2kd) plus ribavirin vs. Interferon alfa-2b plus ribavirin for chronic hepatitis c (chc) in a developing country — Brazil - Value in Health, Vol. 8, Issue 6, A119–A120

 

  • PGI13 A COST UTILITY ANALYSIS OF PEGUINTERFERON ALFA 2B (I2KD) (PEG2B) VERSUS PEGUINTERFERON ALFA 2A (40KD) (PEG2A) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN BRAZIL - Value in Health Vol. 9, Issue 3, Page A47

 

  • PCV23 AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT) IN BRAZIL - Value in Health Vol. 9, Issue 3, Page A125

 

  • PCN41 COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING - Value in Health Vol. 9, Issue 6, Page A288

 

  • PGI21 ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT: A CROSS SECTIONAL EVALUATION IN BRAZIL - Value in Health Vol. 9, Issue 3, Page A49

 

  • PCN32 COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL -  Value in Health Vol. 9, Issue 6, Page A285

 

  • PCN11 IS EARLY REPLACEMENT OF HORMONE THERAPY (HT) BY SEQUENTIAL CHEMOTHERAPY (CT) COST-EFFECTIVE IN HORMONE-RECEPTOR (HR) POSITIVE ADVANCED BREAST CANCER (ABC) - Value in Health Vol. 10, Issue 3, Page A126

 

  • PUK17 STRESS URINARY INCONTINENCE: EFFECT OF OBESITY IN PATIENTS' PERCEPTION OF HEALTH RELATED QUALITY OF LIFE - Value in Health Vol. 10, Issue 3, Page A107

 

  • PSK1 COST EFFECTIVENESS OF THE USE OF INFLIXIMAB COMPARED TO OTHER BIOLOGICAL AGENTS (BA) IN THE SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS - Value in Health Vol. 10, Issue 3, Page A99

 

  • PCN8 COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN FOR THE TREATMENT OF POST MENOPAUSAL HORMONE-RECEPTOR POSITIVE BREAST CANCER (BC) IN THE ADJUVANT SETTING IN BRAZIL - Value in Health Vol. 10, Issue 3, Page A125

 

  • PUK7 GENERIC SUBSTITUTION OF TACROLIMUS AFTER RENAL TRANSPLANTATION: A DECISION-MAKING MODEL TO WEIGH RISKS AND BENEFITS - Value in Health Vol. 10, Issue 3, Page A104

 

  • PGI8 COST OF PATIENT CARE IN PATIENTS WITH CROHN'S DISEASE IN BRAZIL: PUBLIC HEALTH PERSPECTIVE - Value in Health Vol. 10, Issue 3, Page A149

 

  • PCN23 COST EFFECTIVENESS OF CLODRONATE AND ZOLENDRONATE FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BRAZIL: PUBLIC HEALTH PERSPECTIVE - Value in Health Vol. 11, Issue 6, Pages A466-A467

 

  • PGI3 COST OF PATIENT CARE IN PATIENTS WITH ULCERATIVE COLITIS IN BRAZIL: PUBLIC HEALTH PERSPECTIVE - Value in Health Vol. 11, Issue 3, Page A84

 

  • PGI4 A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHN'S DISEASE PATIENTS - Value in Health Vol. 11, Issue 3, Pages A84-A85

 

  • PCN31 ECONOMIC EVALUATION OF CLODRONATE AND ZOLENDRONATE IN PATIENTS DIAGNOSED WITH METASTATIC BONE DISEASE FROM THE PERSPECTIVE OF THIRD PARTY PAYORS IN BRAZIL - Value in Health Vol. 11, Issue 6, Page A469

 

  • PCN5 META-ANALYSIS ON THE MORBIDITY AND MORTALITY OF CLODRONATE, PAMIDRONATE AND ZOLEDRONATE IN PATIENTS WITH BONE METASTASES - Value in Health Vol. 11, Issue 3, Pages A55-A56

 

  • PGI27 INFLAMMATORY BOWEL DISEASES (IBD) PATIENTS PROFILE: FACTS EXTRACTED FROM A MULTICENTER RETROSPECTIVE STUDY - Value in Health Vol. 11, Issue 3, Page A92

 

  • Efficacy of Clodronate, Pamidronate, and Zoledronate in Reducing Morbity and Mortality in Cancer Patients With Bone Metastasis: A Meta-Analysis of Randomized Clinical Trials - Clinical Therapeutics/Volume 31, Number 5

 

  • IMPACT OF THE BRAZILIAN PUBLIC MENTAL HEALTH POLICY ON SCHIZOPHRENIA HOSPITALIZATION: A 10-YEAR ANALYSIS - Value in Health, Vol. 12, Issue 3, A187

 

  • ADMINISTRATIVE CLAIMS IN A LARGE BRAZILIAN NATIONWIDE DATABASE: A DESCRIPTIVE ANALYSIS OF THE DIRECT MEDICAL COSTS OF CORONARY ARTERY BYPASS GRAFTING (CABG) AMONG DIFFERENT REGIONS IN A CONTINENTAL-SIZE COUNTRY - Value in Health, Vol. 12, Issue 3, A154

 

  • Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil - Braz J Infect Dis; 13(3): 191-199, June 2009

 

  • Cost-effectiveness of anastrozole, in comparison with tamoxIfen, in the adjuvant treatment of early breast Cancer in Brazil - Rev Assoc Med Bras 2009; 55(4): 410-5

 

  • PGI5 A BUDGET IMPACT ANALYSIS OF THE HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON IN BRAZIL - Value in Health Vol. 13, Issue 7, Page A369

 

  • PIN13 IMPACT ON COST OF INAPPROPRIATE INITIAL EMPIRICAL USE OF ANTIBIOTIC IN PATIENTS WITH COMPLICATED INFECTIONS FROM TWO LARGE BRAZILIAN HOSPITALS - Value in Health Vol. 13, Issue 3, Page A188

 

  • Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients - Value in Health, Vol. 15, Issue 4, A139

 

  • Cost Effectiveness of Retreatment of Patients with Chronic Hepatitis C (Chc) Who Do Not Respond to Peginterferon Alpha and Ribavirin for 48 Weeks Vs. Peginterferon Alfa and Ribavirin for 72 Weeks - Value in Health, Vol. 15, Issue 4, A139

 

  • Ilusão ou realidade, arte abstrata ou concreta? Modelos em saúde: eles respondem as perguntas? - Rev Assoc Med Bras 2012; 58(3):269-271

 

  • Estimated Cost Effectiveness of Lower-Dose Submicron Diclofenac Compared with Traditional Diclofenac in Brazil - Value in Health Vol. 16, Issue 7, Pages A717-A718

 

  • PGI23 Cost Effectiveness of Retreatment of Patients with Chronic Hepatitis C (Chc) Who Do Not Respond to Peginterferon Alpha and Ribavirin for 48 Weeks Vs. Peginterferon Alfa and Ribavirin for 72 Weeks - Value in Health Vol. 15, Issue 4, Page A139

 

  • Systematic Review Of The Literature And Cost Minimization And Budget Impact Analyses Of The Treatment Of Chronic Obstructive Pulmonary Disease (Copd) With Inhaled Corticoids In Brazil - Value in Health Vol. 16, Issue 3, Page A233

 

  • Use of Antenatal Corticosteroids Lowers Hospitalization Costs Related to Prematurity - Value in Health Vol. 16, Issue 7, Page A332

 

 

 

 

  • Estimated Cost Effectiveness of Lower-Dose Submicron Diclofenac Compared with Traditional Diclofenac in Brazil - Value in Health Vol. 16, Issue 7, Pages A717-A718

 

  • PHP40 REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL: CITEC SUBMISSIONS PROFILE - Value in Health Vol. 13, Issue 7, Page A412

 

  • Consenso brasileiro do tratamento da fibromialgia/ Brazilian consensus on the treatment of fibromyalgia - Rev Bras Reumatol 2010;50(1):56-66

 

  • A survey on clinical presentation and nutritional status of infants with suspected cow' milk allergy - BMC Pediatrics 2010, 10:25

 

  • REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL: CITEC SUBMISSIONS PROFILE - Value in Health, Vol. 13, Issue 7, A412

 

  • A BUDGET IMPACT ANALYSIS OF THE HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON IN BRAZIL - Value in Health, Vol. 13, Issue 7, A369

 

  • PCN89 Public Health Impact of Quadrivalent HPV Types 6, 11, 16, 18 Vaccine in Sao Paulo, Brazil Using A Transmission Dynamic Model - Value in Health Vol. 14, Issue 7, Page A450

 

  • PIN28 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES 6, 11, 16, 18 VACCINE IN BRAZIL USING A TRANSMISSION DYNAMIC MODEL - Value in Health Vol. 14, Issue 3, Page A118

 

  • PHP35 DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT: THE GOOD, THE BAD, AND THE FUTURE - Value in Health Vol. 14, Issue 3, Pages A17-A18

 

  • PHP35 Perceptions, Knowledge and Gaps about HTA and Health Economics by the Braziian Market Stakeholders: Ispor Brazil Qualitative Research - Value in Health Vol. 14, Issue 7, Page A554

 

  • Is Equity of Access to Health Care Achievable in Latin America? -  Value in health 14. 2011. S8-s12

 

  • Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil - Human Vaccines 7:10, 1037-1047; Landes Bioscience

 

  • PGI25 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients - Value in Health Vol. 15, Issue 4, Page A139

 

  • PGI24 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Retreatment of Patients with Chronic Hepatitis C Virus Genotype I Infection - Value in Health Vol. 15, Issue 4, Page A139

 

  • PGI16 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients - Value in Health Vol. 15, Issue 7, Page A328

 

  • PGI21 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Retreatment of Patients With Chronic Hepatitis C Virus Genotype I Infection - Value in Health Vol. 15, Issue 7, Page A329

 

  • PCV56 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at LDL Cholesterol Treatment Goal in Brazil - Value in Health Vol. 15, Issue 7, Page A372

 

  • PMS41 Cost-Effectiveness of Denosumab in Preventing Osteoporotic Fractures in Postmenopausal Women from the Private Health Care Setting Perspective in Brazil - Value in Health Vol. 15, Issue 7, Pages A446-A447

 

  • Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model - BMC Infectious Diseases 2012, 12:250

 

  • Systematic Review Comparing the Efficacy of the 5-Alpha Reductase Inhibitors (5-Aris) Dutasteride and Finasteride in the Treatment of Benign Prostatic Hyperplasia (BPH) - Value in Health, Vol. 15, Issue 4, A192

 

  • Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Retreatment of Patients With Chronic Hepatitis C Virus Genotype I Infection - Value in Health, Vol. 15, Issue 7, A329

 

  • Hip and knee arthroplasty: How much these procedures impacts in the brazilian health care expenditures? - Value in Health, Vol. 16, Issue 3, A229–A230

 

  • HTA process in Brazil: How far the submitters are from the inclusion in the system? - Value in Health, Vol. 16, Issue 3, A253

 

  • Supplementary health care utilization research in Brazil: Characterization of the BI.2IM database - Value in Health, Vol. 16, Issue 3, A203

 

  • Multi-payers comparison of daily reimbursement values of distinct hospital facilities in the Brazilian private health system - Value in Health, Vol. 16, Issue 3, A208

 

  • The profile of the actinic keratosis (ak) patients in the city of São Paulo - Project Pilot - Value in Health, Vol. 16, Issue 3, A179–A180

 

  • The profile of solar exposition and use of sunscreening agents use of patients from São Paulo city with actinic keratosis (ak) - Value in Health, Vol. 16, Issue 3, A18

 

  • Does HTA Process Help to Achieve the Health Objectives of the Millennium? A South American Analysis - Value in Health, Vol. 16, Issue 7, A490

 

  • Systematic Literature Review and Cost-effectiveness Analysis of Fetal Fibronectin Test for Predicting Preterm in Brazil - Value in Health, Vol. 16, Issue 7, A333–A334

 

  • Autism: Patient profile, economic and social impact in a developing country - Value in Health Vol. 17, Issue 3, Page A218

English

 Português

bottom of page